Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2012

London (October 19, 2012) – At the start of its October 2012 meeting, the Committee for Medicinal Products for Human Use (CHMP) elected Dr Ian Hudson as its new vice-chair for a three-year mandate.
Dr Hudson brings outstanding experience and expertise from a long career in regulatory medicine and drug development, particularly in the areas of anti-infectives and oncology. He currently holds the position of Director of the Licensing Division at the Medicines & Healthcare Products Regulatory Agency in London. Dr Hudson has been a member of CHMP since 2004.
The opinions adopted by the CHMP at the October 2012 meeting and other important outcomes are listed in the table below.

Positive recommendations on new medicines

Name of medicine

Amyvid

International non-proprietary name (INN)

florbetapir (18F)

Marketing-authorisation applicant

Eli Lilly Nederland BV

Therapeutic indication

Radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β -amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment

More information

Summary of opinion for Amyvid

Press release: European Medicines Agency recommends approval of first radiopharmaceutical for PET imaging of β -amyloid neuritic plaque density

Name of medicine

Betmiga

International non-proprietary name (INN)

mirabegron

Marketing-authorisation applicant

Astellas Pharma Europe BV

Therapeutic indication

Treatment of overactive bladder syndrome

More information

Summary of opinion for Betmiga

Name of medicine

Krystexxa

International non-proprietary name (INN)

pegloticase

Marketing-authorisation applicant

Savient Pharma Ireland Ltd

Therapeutic indication

Treatment of chronic gout

More information

Summary of opinion for Krystexxa

Name of medicine

Tresiba

International non-proprietary name (INN)

insulin degludec

Marketing-authorisation applicant

Novo Nordisk A/S

Therapeutic indication

Treatment of diabetes mellitus

More information

Summary of opinion for Tresiba

Press release: European Medicines Agency recommends approval of first higher-strength insulin for treatment of patients with diabetes mellitus in the EU

Name of medicine

Ryzodeg

International non-proprietary name (INN)

insulin degludec / insulin aspart

Marketing-authorisation applicant

Novo Nordisk A/S

Therapeutic indication

Treatment of diabetes mellitus

More information

Summary of opinion for Ryzodeg


Negative recommendations on new medicines

Name of medicine

Acrescent

International non-proprietary name (INN)

memantine hydrochloride / donepezil hydrochloride

Marketing-authorisation applicant

H. Lundbeck A/S

Therapeutic indication

Treatment of Alzheimer’s disease

More information

Questions and answers on Acrescent

Name of medicine

Balaxur

International non-proprietary name (INN)

memantine hydrochloride / donepezil hydrochloride

Marketing-authorisation applicant

Merz Pharmaceuticals GmbH

Therapeutic indication

Treatment of Alzheimer’s disease

More information

Questions and answers on Balaxur

Name of medicine

Qsiva

International non-proprietary name (INN)

phentermine / topiramate

Marketing-authorisation applicant

Vivus BV

Therapeutic indication

Treatment of obesity

More information

Questions and answers on Qsiva

Positive recommendations on extensions of therapeutic indications

Name of medicine

Humira

International non-proprietary name (INN)

adalimumab

Marketing-authorisation holder

Abbott Laboratories Ltd

New therapeutic indication

Paediatric Crohn’s Disease

Humira is indicated for the treatment of severe active Crohn’s disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies.
Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

More information

Summary of opinion for Humira

Name of medicine

Isentress

International non-proprietary name (INN)

raltegravir

Marketing-authorisation holder

Merck Sharp & Dohme Ltd

Therapeutic indication
(changes in bold)

Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, and children from the age of 2 years.

More information

Summary of opinion for Isentress

Name of medicine

Thyrogen

International non-proprietary name (INN)

thyrotropin alfa

Marketing-authorisation holder

Genzyme Europe BV

Therapeutic indication
(changes in bold)

Thyrogen is indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post-thyroidectomy patients maintained on hormone suppression therapy (THST).
Low risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh (recombinant human) TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels.
Thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mCi (1.1 GBq) to 100 mCi (3.7 GBq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.4).

More information

Summary of opinion for Thyrogen

Name of medicine

Xarelto

International non-proprietary name (INN)

rivaroxaban

Marketing-authorisation holder

Bayer Pharma AG

Therapeutic indication
(changes in bold)

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)

More information

Summary of opinion for Xarelto

Positive recommendations on new generic medicines

Name of medicine

Imatinib Teva

International non-proprietary name (INN)

imatinib

Marketing-authorisation applicant

Teva Pharma BV

Therapeutic indication

Treatment of leukaemia

More information

Summary of opinion for Imatinib Teva


Outcomes of arbitration procedures

Name of medicine

INN

Marketing authorisation applicant

furosemide

Vitabalans Oy

levothyroxine

Alapis SA


Re-examination of arbitration procedure

Name of medicine

INN

Marketing authorisation applicant

loratadine

Vitabalans Oy


Re-examination of safety review

Name of medicine

Outcomes of Art.5(3) reviews

Other updates

  • Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures


European Medicines Agency, 19.10.2012 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 
Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung